natgillin/translations-raw huggingface dataset:
Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 CD34+ cells/kg recipient bodyweight.
Leukaferezu je potrebno započeti dana i, ako je potrebno, nastaviti do 6. dana kako bi se prikupilo 4 x 106 CD34+ stanica/kg tjelesne težine primatelja.
Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 CD34+ cells/kg recipient bodyweight.
Leukaferezu treba početi 5. dan i nastaviti do 6. dana bude li potrebno da se prikupi 4 x 106 CD34+ stanica/kg tjelesne težine primatelja.
leukemia (cancer affecting the blood and bone marrow);
leukemija (rak koji zahvaća krv i koštanu srž),
Leukocyte Activation Syndrome (APL Differentiation Syndrome): 27% of patients with APL treated with TRISENOX have experienced symptoms similar to a syndrome called the retinoic-acid-acute promyelocytic leukaemia (RA-APL) or APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis.
Sindrom aktivacije leukocita (sindrom diferencijacije APL-a): U 27% bolesnika s APL-om liječenih TRISENOXOM pojavili su se simptomi slični sindromu zvanom sindrom retinoične kiseline u akutnoj promijelocitnoj leukemiji (RA-APL) ili sindrom diferencijacije APL-a, koji karakteriziraju vrućica, dispneja, porast tjelesne težine, plućni infiltrati i pleuralni ili perikardijalni izljevi s leukocitozom ili bez nje.
leukocyte count < 3000/mm³
broj leukocita < 3000/mm³
Leukocytes decreased
nižen broj leukocita
Leukocytes Decreased
niženi broj leukocita
leukocytoclast
leukocitoklastičn
Leukocytoclast ic vasculitis Purpura Angioedema*
Leukocitoklast ični vaskulitis Purpura Angioedem
leukocytoclastic vasculitis
leukocistoklastični vaskulitis
leukocytoclastic vasculitis, skin fibrosis
leukocitoklastični vaskulitis, kožna fibroza
leukocytopenia, thrombocytopenia
leukocitopenija, trombocitopenija
Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, hypertonia, peripheral neuropathy, myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation), vasculitis, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, hepatic enzymes increased*, angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity.
Leukocitopenija, trombocitopenija, alergijske reakcije, hiperglikemija, hipertonija, periferna neuropatija, infarkt miokarda, aritmija (uključujući bradikardiju, ventrikularnu tahikardiju i fibrilaciju atrija), vaskulitis, pankreatitis, gastritis, hiperplazija gingive, hepatitis, žutica, povišenje jetrenih enzima*, angioedem, multiformni eritem, urtikarija, eksfolijativni dermatitis, Stevens-Johnsonov sindrom, Quinckeov edem, fotosenzitivnost.
Leukocytosis (WBC > 50 x 109/L) was observed in 41 % of donors and transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim and leukapheresis was observed in 35 % of donors.
Leukocitoza (leukociti > 50 x 109/l) je uočena u 41 %, a prolazna trombocitopenija (trombociti < 100 x 109/l) u 35 % davatelja nakon primjene filgrastima i leukafereze.
Leukocytosis (WBC > 50 x 109/l) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (leukociti > 50 x 109/l) je primijećena u 41 % davatelja, dok je prolazna trombocitopenija (trombociti < 100 x 109/l) nakon filgrastima i leukafereze primijećena u 35 % davatelja (vidjeti dio 4.4).
Leukocytosis (WBC > 50 x 109/L) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim treatment and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (L > 50 x 109/l) je bila opažena u 41% darivatelja, kao i prolazna trombocitopenija (trombociti < 100 x 109/l) nakon liječenja filgrastimom i leukafereza je bila opažena u 35% darivatelja (vidjeti dio 4.4).
Leukocytosis (WBC > 50 x 109/L) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim treatment and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (L > 50 x109/l) je bila opažena u 41% darivatelja, kao i prolazna trombocitopenija (trombociti < 100 x109/l) nakon liječenja filgrastimom i leukafereza je bila opažena u 35% darivatelja (vidjeti dio 4.4).
Leukocytosis (WBC > 50 x 109/L) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim treatment and leukapheresis was observed in 35% of donors.
Leukocitoza (L > 50 x109/l) je bila opažena u 41% darivatelja, kao i prolazna trombocitopenija (trombociti < 100 x109/l) nakon liječenja filgrastimom i leukafereza je bila opažena u 35% darivatelja..
Leukocytosis (white blood cell (WBC) > 50 x 109/l) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza (broj bijelih krvnih stanica >50 x 109/l) je uočena u 41% davatelja, a prolazna trombocitopenija (trombociti <100 x 109/l) u 35% davatelja nakon primjene filgrastima i leukafereze (vidjeti dio 4.4).
Leukocytosis occurred in 50% of patients with APL, as determined by haematology assessments.
Leukocitoza se pojavila u 50% bolesnika s APL-om, kako je to utvrđeno hematološkim pretragama.
Leukocytosis was observed in donors and thrombocytopenia following filgrastim and leukapheresis was also observed in donors.
U darivatelja je bila opažena leukocitoza, kao i trombocitopenija nakon filgrastima i leukafereze.
Leukocytosis was observed in donors and thrombocytopenia following filgrastim and leukapheresis was also observed in donors.
U davatelja je zabilježena leukocitoza, a trombocitopenija nakon filgrastima i leukafereze je također zabilježena u davatelja.
Leukocytosis was observed in donors andthrombocytopenia following filgrastim and leukapheresis was also observed in donors.
U davatelja je zabilježena leukocitoza, a trombocitopenija nakon primjene filgrastima i leukafereze je također zabilježena u davatelja.
Leukocytosis*, Splenomegaly*
leukocitoza*, splenomegalija
Leukocytosis, Lymphadenopathy
leukocitoza, limfadenopatija
Leukocytosis, thrombocytopenia
Leukocitoza, trombocitopenija
Leukocytosisa
leukocitozaa
Leukoenceph- alopathy, anosmia
leukoencefalopatija, anosmija
Leukoencephalopathy
Leukoencefalo- patija
Leukopaenia **
leukopenija
Leukopaenia, anaemia
leukopenija, anemija
Leukopaenia, anaemia, neutropaenia, thrombocytopaenia
leukopenija, anemija, neutropenija,
Leukopaenia, anaemia, neutropaenia, thrombocytopaenia
leukopenija, anemija, neutropenija, trombocitopenija
Leukopaenia, anaemia, thrombocytopaenia
leukopenija, anemija, trombocitopenija
Leukopenia
Leukocitoza Limfopenija
Leukopenia
leukopenija
Leukopenia (Leukopenia, White blood cell count decreased).
Leukopenija (leukopenija, smanjeni broj leukocita). d..
Leukopenia Neutropenia Thrombocytopenia
leukopenija neutropenija trombocitopenija
Leukopenia Thrombocytopaenia
leukopenija trombocitopenija
Leukopenia Thrombocytopenia
leukopenija, trombocitopenija
Leukopenia Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia Granulocytopenia
Leukopenija Trombocitopenija Febrilna neutropenija Anemija Pancitopenija Granulocitopenija
Leukopenia*
leukopenija
Leukopenia**** Neutropenia**** Anemia****
leukopenija**** neutropenija**** anemija
Leukopenia*, Lymphopenia*
Leukopenija*, limfopenija
Leukopenia*, thrombocytopenia*, pancytopenia, agranulocytosis
leukopenija*, trombocitopenija*, pancitopenija, agranulocitoza
Leukopenia, lymph node pain
leukopenija, bol u limfnom čvoru
Leukopenia, Neutropenia
leukopenija, neutropenija
leukopenia, neutropenia, anaemia
leukopenija, neutropenija, anemija
Leukopenia, neutropenia, and agranulocytosis
Leukopenija, neutropenija i agranulocitoza
Leukopenia, thrombocytopenia
leukopenija, trombocitopenija
Leukopenia, thrombocytopenia, anaemia
leukopenija, trombocitopenija, anemija
Leukopenia, Thrombocytopenia, Granulocytopenia, Febrile neutropenia
Leukopenija, Trombocitopenija, Granulocitopenija, Febrilna neutropenija
Leukopeniaa
leukopenijaa
Leukopeniaam, thrombocytopeniaam
Leukopenijaam, trombocitopenijaam
Leukostasis syndrome
Angioedem
Leukostasis syndrome
Febrilna neutropenija
Leuprorelin 7.5 mg
Leuprorelin 7,5 mg
Leuprorelin 7.5 mg N=201
Leuprorelin 7,5 mg N=201
Level 1 dose reduction: From 35 mg/m2 to 30 mg/m2
Stupanj 1 smanjenja doze: Sa 35 mg/m2 na 30 mg/m2
Level 2 dose reduction: From 30 mg/m2 to 25 mg/m2
Stupanj 2 smanjenja doze: Sa 30 mg/m2 na 25 mg/m2
Level 3 dose reduction: From 25 mg/m2 to 20 mg/m2
Stupanj 3 smanjenja doze: Sa 25 mg/m2 na 20 mg/m2
level carefully monitored.
pažljivo kontrolirati razinu
Level of the antibody response (index) for patients without a history of immunosuppressant treatment
Razina odgovora protutijela (indeks) za bolesnike bez imunosupresivnog liječenja u anamnezi
levels achieved in the blood might influence the rate of lung density
moglo utjecati na brzinu smanjenja gustoće pluća te bi li to podržalo
Levels appeared to return to normal after treatment discontinuation and did not appear to have any clinical consequences. d Data from a double blind placebo controlled study showed a median increase (in percentage change from baseline) up to 23% remaining consistent over time and returning to baseline after treatment discontinuation, with no apparent clinical sequelae.
Razine su se vratile na normalne vrijednosti nakon prekida liječenja i čini se da nisu imale nikakvih kliničkih posljedica. d Podaci iz dvostruko slijepog, placebom kontroliranog ispitivanja ukazali su na medijan povećanja (u postocima promjene od početne vrijednosti) do 23%, koje se održalo na istoj razini tijekom vremena te se vratilo na početnu vrijednost nakon prekida liječenja, bez vidljivih kliničkih posljedica.
Levels of amyloid A were also reduced.
Razine amiloida A također su smanjene.
Levels of approximately 0.2, 0.4, 1.0 and 1.3 IU/mL of anti-Xa were seen in healthy volunteers, following a single subcutaneous administration of 20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg, respectively.
Razine anti-Xa aktivnosti od približno 0,2; 0,4; 1,0 i 1,3 IU/ml primijećene su u zdravih dobrovoljaca nakon jednokratne supkutane primjene 20 mg, 40 mg, 1 mg/kg i 1,5 mg/kg.
Levels of approximately 0.2, 0.4, 1.0 and 1.3 IU/mL of anti-Xa were seen in healthy volunteers, following a single subcutaneous administration of 20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg, respectively.
Razine anti-Xa aktivnosti od približno 0,2; 0,4; 1,0 i 1,3 IU/ml primijećene su u zdravih dragovoljaca nakon jednokratne supkutane primjene 20 mg, 40 mg, 1 mg/kg i 1,5 mg/kg.
Levels of HLA- DR (a measure of inflammation in eye cells) were also reduced in patients using Ikervis compared with the dummy treatment.
Koncentracije HLA-DR (mjere upale stanica oka) također su se smanjile u bolesnika koji su koristili Ikervis u usporedbi s lažnim liječenjem.
Levels of tegafur, gimeracil, oteracil and 5-FU were quantifiable through 10 hours postdose.
Razine tegafura, gimeracila, oteracila i 5-FU-a bile su mjerljivee kroz 10-sati nakon primjene.
Levemir 100 units/ml
Levemir 100 jedinica/ml
Levemir 100 units/ml solution for injection in cartridge.
Levemir 100 jedinica/ml otopina za injekciju u ulošku.
Levemir 100 units/ml solution for injection in pre-filled pen.
Levemir 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici.
Levemir can be used in adolescents and children aged 1 year and above.
Levemir se može primjenjivati u adolescenata i djece u dobi od 1 ili više godina.
Levemir can be used in older patients.
Levemir se može koristiti u starijih bolesnika.
Levemir contains less than 1 mmol sodium (23 mg) per dose, i.e.
Levemir sadrži manje od 1 mmol (23 mg) natrija po dozi, tj.
Levemir FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Levemir FlexPen napunjena je brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist, duljine do 8 mm.
Levemir FlexPen is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
Levemir FlexPen označen je bojom i uz njega je priložena Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
Levemir FlexTouch is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Levemir FlexTouch napunjena je brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist, duljine do 8 mm.
Levemir FlexTouch is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
Levemir FlexTouch označen je bojom i uz njega je priložena Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
Levemir has a long and steady blood-sugar-lowering action within 3 to 4 hours after injection.
Levemir ima dugo i ravnomjerno djelovanje na snižavanje razine šećera u krvi, koje nastupa unutar 3 do 4 sata od injiciranja.
Levemir InnoLet and FlexTouch
Levemir InnoLet i FlexTouch
Levemir InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Levemir InnoLet napunjena je brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist, duljine do 8 mm.
Levemir InnoLet is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Levemir InnoLet priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
Levemir is essentially ‘sodium-free’.
Levemir sadrži zanemarive količine natrija.
Levemir is given as an injection under the skin in the abdominal (tummy) wall, the thigh, the upper arm, the shoulder or the buttock.
Levemir se primjenjuje injekcijom ispod kože u abdomeni (trbušni) zid, bedro, nadlakticu, rame ili gluteus.
Levemir once daily
Levemir jedanput dnevno
Levemir Penfill and FlexPen
Levemir Penfill i FlexPen
Levemir Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Levemir Penfill priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
Levemir was non-inferior to NPH insulin as measured by HbA1c at gestational week (GW) 36, and the reduction in mean HbA1c through pregnancy was similar, see table 4.
Levemir nije bio inferioran NPH inzulinu s obzirom na HbA1c u 36. tjednu trudnoće (TT), a sniženje prosječne vrijednosti HbA1c bilo je slično tijekom cijele trudnoće, vidjeti Tablicu 4.
Levemir was studied in an open-label randomised controlled clinical trial pregnant women with type 1 diabetes (n=310) were treated in a basal-bolus treatment regimen with Levemir (n=152) or NPH insulin (n=158) as basal insulin, both in combination with NovoRapid (see section 4.6).
Levemir je ispitan u otvorenom, randomiziranom, kontroliranom kliničkom ispitivanju, u kojemu su trudnice koje imaju šećernu bolest tipa 1 (n=310) liječene bazal-bolus terapijom u kojoj su Levemir (n=152) ili NPH inzulin (n=158) primjenjivani kao bazalni inzulin i u oba slučaja kombinirani s lijekom NovoRapid (vidjeti dio 4.6).
Levemir was the basal insulin product for 33% (N = 147) of the patients (97.3% using metformin).
Levemir je kao bazalni inzulin primjenjivalo ukupno 33% (N = 147) bolesnika (od kojih je 97,3% uzimalo i metformin).
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam primijenjen u dozi od 1000 mg na dan nije utjecao na farmakokinetiku oralnih kontraceptiva (etinil-estradiola i levonorgestrela); endokrini pokazatelji (luteinizirajući hormon i progesteron) ostali su nepromijenjeni.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam primijenjen u dozi od 1000 mg na dan nije utjecao na farmakokinetiku oralnih kontraceptiva (etinilestradiola i levonorgestrela); endokrini pokazatelji (luteinizirajući hormon i progesteron) ostali su nepromijenjeni.
Levetiracetam 100mg/ml oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from 6 to 17 years) weighing less than 50 kg and when tablets don’t allow accurate dosage.
Levetiracetam 100 mg/ml oralna otopina je prikladniji farmaceutski oblik za primjenu u dojenčadi i djece mlađe od 6 godina, djece i adolescenata (od 6-17 godina) tjelesne težine manje od 50 kg te kada se tabletama ne može postići točno doziranje.
Levetiracetam Accord 1000 mg film-coated tablets
Levetiracetam Accord 1000 mg filmom obložene tablete
Levetiracetam Accord 1000 mg film-coated tablets Levetiracetam
Levetiracetam Accord 1000 mg filmom obložene tablete levetiracetam
Levetiracetam Accord 250 mg film-coated tablet Levetiracetam
Levetiracetam Accord 250 mg filmom obložena tableta levetiracetam
Levetiracetam Accord 250 mg film-coated tablets
Levetiracetam Accord 250 mg filmom obložene tablete
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam
Levetiracetam Accord 250 mg filmom obložene tablete levetiracetam
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets Levetiracetam
Levetiracetam Accord 250 mg filmom obložene tablete Levetiracetam Accord 500 mg filmom obložene tablete Levetiracetam Accord 750 mg filmom obložene tablete Levetiracetam Accord 1000 mg filmom obložene tablete levetiracetam
Levetiracetam Accord 500 mg film-coated tablets
Levetiracetam Accord 500 mg filmom obložene tablete
Levetiracetam Accord 500 mg film-coated tablets Levetiracetam
Levetiracetam Accord 500 mg filmom obložene tablete levetiracetam
Levetiracetam Accord 750 mg film-coated tablet Levetiracetam
Levetiracetam Accord 750 mg filmom obložene tablete levetiracetam
Levetiracetam Accord 750 mg film-coated tablets
Levetiracetam Accord 750 mg filmom obložene tablete
Levetiracetam Accord film-coated tablets 250 mg, 500 mg, 750 mg and 1000 mg are packed in PVC-Alu blister pack.
Levetiracetam Accord filmom obložene tablete 250 mg, 500 mg, 750 mg i 1000 mg se pakiraju u PVC- Al blister pakiranja.
Levetiracetam Accord has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
U ispitivanjima na životinjskim modelima, utvrđeno je da je Levetiracetam Accord povezan s neželjenim reproduktivnim učincima kada je primjenjivan u dozama većim nego što bi bile potrebne za kontrolu Vaših napadaja.
Levetiracetam Accord is not indicated in children and adolescents below 16 years on its own (monotherapy).
U djece i adolescenata mlađih od 16 godina Levetiracetam Accord se ne primjenjuje samostalno (monoterapija).
Levetiracetam Accord is used as a chronic treatment.
Levetiracetam Accord se koristi za kronično liječenje.
Levetiracetam Accord should not be used during pregnancy unless clearly necessary.
Levetiracetam Accord se ne smije uzimati tijekom trudnoće, osim ako je to neophodno.
Levetiracetam Actavis 1,000 mg film-coated tablets
Levetiracetam Actavis 1000 mg filmom obložene tablete.
Levetiracetam Actavis 1,000 mg tablets are oval, white, 19.0 x 10.0 mm marked with “L” on one side and “1000” on the other side.
Levetiracetam Actavis 1000 mg filmom obložene tablete su ovalne, bijele tablete, veličine 19,0 x 10,0 mm s oznakom „L” na jednoj strani i „1000“ na drugoj strani.
Levetiracetam Actavis 250 mg film-coated tablets
Levetiracetam Actavis 250 mg filmom obložene tablete.
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1,000 mg film-coated tablets
Levetiracetam Actavis 250 mg filmom obložene tablete Levetiracetam Actavis 500 mg filmom obložene tablete Levetiracetam Actavis 750 mg filmom obložene tablete Levetiracetam Actavis 1000 mg filmom obložene tablete
Levetiracetam Actavis 250 mg, 500 mg and 1,000 mg film-coated tablets
Levetiracetam Actavis 250 mg, 500 mg i 1000 mg filmom obložene tablete
Levetiracetam Actavis 500 mg film-coated tablets
Levetiracetam Actavis 500 mg filmom obložene tablete.
Levetiracetam Actavis 500 mg tablets are oval, yellow, 17.1 x 8.1 mm marked with “L” on one side and “500” on the other side.
Levetiracetam Actavis 500 mg filmom obložene tablete su ovalne, žute tablete, veličine 17,1 x 8,1 mm s oznakom „L” na jednoj strani i „500“ na drugoj strani.
Levetiracetam Actavis 750 mg film-coated tablets
Levetiracetam Actavis 750 mg filmom obložene tablete.
Levetiracetam Actavis 750 mg tablets are oval, orange, 19.0 x 9.3 mm marked with “L” on one side and “750” on the other side.
Levetiracetam Actavis 750 mg filmom obložene tablete su ovalne, narančaste tablete, veličine 19,0 x 9,3 mm s oznakom „L” na jednoj strani i „750“ na drugoj strani.
Levetiracetam Actavis is indicated as adjunctive therapy
Levetiracetam Actavis je indiciran kao dodatna terapija
Levetiracetam Actavis is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.
Ne preporučuje se primjena lijeka Levetiracetam Actavis tijekom trudnoće i u žena u reproduktivnoj dobi koje ne uzimaju kontracepciju, osim ako to nije klinički neophodno.
Levetiracetam Actavis is used as a chronic treatment.
Levetiracetam Actavis se koristi za dugotrajno liječenje.
Levetiracetam Actavis is used:
Levetiracetam Actavis se koristi:
Levetiracetam Actavis may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Ako vozite ili upravljate alatima ili vozilima potreban je oprez jer se pri uzimanju lijeka jer se može javiti osjećaj pospanosti.
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Djelotvornost levetiracetama dokazana je u dvostruko-slijepoj i s placebom kontroliranoj studiji u trajanju od 24 tjedna, koja je uključivala odrasle, adolescente i ograničeni broj djece s idiopatskom generaliziranom epilepsijom s primarno generaliziranim toničko-kloničkim (PGTK) napadajima kod različitih sindroma (juvenilna mioklonična epilepsija, epilepsija s apsansima dječje i juvenilne dobi ili epilepsija s grand mal napadajima kod buđenja).
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study, which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Djelotvornost levetiracetama dokazana je u dvostruko-slijepoj i placebom kontroliranoj studiji u trajanju od 24 tjedna, koja je uključivala odrasle, adolescente i ograničeni broj djece s idiopatskom generaliziranom epilepsijom s primarno generaliziranim toničko-kloničkim (PGTK) napadajima kod različitih sindroma (juvenilna mioklonična epilepsija, epilepsija s apsansima dječje i juvenilne dobi ili epilepsija s grand mal napadajima kod buđenja).